調査・レポート
2026年9月14日•1分で読めます
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
調査・レポート
2026年8月30日•1分で読めます
Targeted Therapies Transform Atopic Dermatitis Treatment
Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.